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Over the past two decades, the outcome of patients with Ewing’s
sarcoma has improved considerably. Most of the progress has been
possible due to the development of effective chemotherapy regi-
mens aimed at preventing distant metastases, the demonstrated
cause of death in over 80% of cases. However, since the dramatic
improvement experienced during the 1970s and 1980s, survival
rates have plateaued, with little improvement reported beyond the
50% threshold (Nesbit et al, 1990; Wilkins et al. 1986; Jurgens
et al, 1988a; Bacci et al, 1985; Barbieri et al, 1990; Kinsella et al,
1991). 
In the first study of the French Society of Pediatric Oncology
(SFOP), 95 patients with localized disease were initially treated,
from 1978 to 1982, with combined chemotherapy comprising
vincristine, dactinomycin, doxorubicin and cyclophosphamide
followed by high-dose radiation therapy (45 to 60 Gy according to
the location of the tumour). At 5 years, disease-free survival was
51%. In this study, surgical resection was selected for the small
group of patients with expendable bones such as the ribs or the
fibula (Oberlin et al, 1985). 
In 1984, the SFOP initiated the EW84 study with several goals: 
(1) to improve the efficacy of chemotherapy by introducing 
ifosfamide to replace cyclophosphamide; 
(2) to obtain better local control by extending the indications for
surgical resection of the primary; and 
(3) to reduce therapy-induced late effects by decreasing the 
radiation doses in patients undergoing surgery.
This study concluded that ifosfamide did not afford a further
benefit for long-term disease control compared to the previous
study. However, half of the patients had undergone conservative
surgery and two-thirds of them had received no or reduced doses
of radiation therapy that will very likely decrease long-term
sequelae (Oberlin et al, 1992). 
In 1983, Hayes et al from the St Jude Children’s Research
Hospital in Memphis reported that previously untreated
Ewing’s sarcoma had achieved a dramatic response rate
following moderate-dose, 2-drug, sequentially-scheduled induc-
tion chemotherapy (Hayes et al, 1983). Patients with localized
or metastatic disease were given cyclophosphamide at a dose
of 150 mg/m2 for 7 days followed by 35 mg/m2 of doxorubicin
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semi-continuous chemotherapy and aiming to peform surgery in all; (2) To identify early prognostic factors to tailor therapy for future studies.
Patients and methods One hundred and forty-one patients were entered onto the trial between January 1988 and December 1991. Induction
therapy consisted of five courses of Cytoxan, 150 mg/m2 × 7 days, followed by Doxorubicin, 35 mg/m2 i.v on day 8 given at short intervals.
Surgery was recommended whenever possible. The delivery of radiation therapy was based on the quality of resection and the histological
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(DFS) was 58%. In patients treated by surgery, only the histological response to CT had an influence on survival: 75% DFS for patients with
a good histological response (less than 5% of cells), 48% for intermediate responders and only 20% for poor responders (≥ 30% of cells),
P < 0.0001. The initial tumor volume by itself had no influence on DFS in these patients. In contrast, the tumour volume had a strong impact
on DFS in patients treated by radiation therapy alone. Age had no impact on outcome. Conclusion Therapeutic trials for localized Ewing’s
sarcoma should be based on the histological response to chemotherapy or on the tumour volume according to the modality used for local
therapy. © 2001 Cancer Research Campaign http:www.bjcancer.com 
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on day 8. Five cycles were given before a clinical or surgical
evaluation (Hayes et al, 1983). In 1989, the same team reported
the overall results of this therapy for localized tumours. In
terms of local therapy, only bones known to be expendable
were submitted to surgery. Patients with a complete tumour
resection received no irradiation. Patients with positive margins
received 35–41 Gy. Patients with an unresected primary
received radiotherapy, the dose and target volume being
dependent on response to this induction chemotherapy: 30–
35 Gy after a good response to chemotherapy or 50 Gy if there
was gross residual tumour in soft tissue. Maintenance
chemotherapy consisted of vincristine, dactinomycin, cyclo-
phosphamide, and doxorubicin for a total duration of therapy
of 10 months. The 5-year survival estimate for all the patients
was 80%, comparing favourably with the other published series.
Most of the relapses were local relapses after 35 Gy radiation
(Hayes et al, 1989). 
The third study, initiated by the SFOP in November 1987 had
several aims: 
(1) to confirm the effectiveness of such semi-continuous
chemotherapy in preventing metastases; 
(2) to improve the local control rate observed in the Memphis
study by resecting the primary as often as possible; 
(3) to reduce long-term sequelae by reducing the radiation doses
and avoiding radiation therapy in selected cases; and 
(4) to assess the prognostic value of factors such as the size of 
the primary, age, LDH, erythrocyte sedimentation rate, the
histogical response to chemotherapy, neuroectodermal 
differentiation of the tumour. 
PATIENTS AND METHODS 
Patient selection 
All patients had untreated localized small round-cell bone
tumours of neuroectodermal origin, excluding lymphoma, rhabdo-
myosarcoma and neuroblastoma. Lesions included typical or
conventional ES and atypical ES, malignant peripheral primitive
neuroectodermal tumours of bone (PNET) and Askin’s tumours of
the thoracic wall. 
There was no upper age limit prohibiting entry on the study.
Informed consent was obtained from the parents or guardian of
each child or from the adult patient according to the Declaration of
Helsinki. 
Histopathology 
The diagnosis in all cases was based on the histological analysis of
biopsy samples. A panel of reference pathologists reviewed the
histopathological material to confirm the diagnosis. Each diag-
nosis was based on the presence of small round cells occurring in
the bone, with no histologic, cytologic or immunohistochemical
features of lymphoma, rhabdomyosarcoma, or neuroblastoma.
Tumours were classified into one of two categories: typical
Ewing’s sarcoma (TES) characterized by undifferentiated cells
and devoid of neural markers or so-called peripheral neuroecto-
dermal tumor (PNET) bearing neural features defined as positivity
of at least one of two neural differentiation antigens (e.g., NSE or
S-100 protein) by immunochemistry or the presence of Homer-
Wright rosettes. 
Pretreatment evaluation 
Staging procedures consisted of X-rays and computed tomography
(CT) scans of the primary site and chest and a whole-body tech-
netium bone scan. Primary tumours of the rib with even malignant
pleural effusion were considered as localized disease and included
in the study. Multiple aspirates and 2 biopsies were performed
to assess bone marrow. The tumour volume was estimated by
determining the three dimensions of the primary bone tumour and
of the soft tissue mass on the pretreatment CT and the tumour
volume was calculated according to the previously reported
formula: volume = a × b × c × 0.52 for ‘ellipsoidal tumours’ or 
a × b × c × 0.785 for ‘cylindrical tumours’ (a: the maximal tumour
dimension; b: tumour dimension perpendicular to a; c: the longi-
tudinal maximum tumour dimension) (Gobel et al, 1987).
Pretreatment chemical laboratory tests consisted of serum LDH
measurement and erythrocyte sedimentation rate. 
Chemotherapy 
Chemotherapy protocol was similar to that published by
Hayes et al (Hayes et al, 1989). All patients received induction
chemotherapy with five courses of cyclophosphamide, 150 mg/m2
for 7 days followed on day 8 by doxorubicin, 35 mg/m2 with
courses beginning on days 1, 15, 29, 50, and 71 (Figure 1).
Cyclophosphamide was given i.v. for the first course and orally for
the subsequent courses, without mesna. Patients were re-evaluated
on weeks 12–13 for clinical response to chemotherapy. 
Radiological response assessment was based on the reduction of
the soft tissue mass and graded as a complete response (complete
disappearance of soft tissue mass), a partial response (more than
50% regression of soft tissue mass), no response (0–50% reduction
of the soft tissue mass), progressive disease (any increase in the
soft tissue mass), undulating response (early recurrence of symp-
toms during chemotherapy). 
Local therapy was initiated on week 14. Surgical resection of
the primary was recommended not only for bones known to be
expendable but also for bones requiring replacement by an endo-
prosthesis or allograft. The surgical specimen was examined by
the local pathologist to determine the histological response based
on a grading system derived from Huvos’s grading system for
osteosarcoma (Huvos et al, 1977). Response was scored according
to 3 grades: minimal residual disease (no identifiable viable
tumour or less than 5% of identifiable residual tumor cells),
moderate effect (5–30% of identifiable residual tumour cells) and
no or small effect (more than 30% of identifiable residual tumour
cells). 
INDUCTION CT RADIATION TH. MAINTENANCE CT
S
U
R
G
E
R
Y
Cyclo  ×   7
Doxo   ×   1
w.1, 3, 5, 8,11 
−  < 5% residual cells
             RT = 0
Dactino  ×   6
VCR      ×   11
Cyclo ×   7
Doxo  ×   1
−  No or incomplete S.
     RT = 45 to 60 GY
−  Other situations
      RT = 40 GY
+
×   6
Figure 1 Outline of the treatment schedule. CT = chemotherapy, 
TH = therapy, S = surgery, RT = radiation therapy, Gy = grays,
Cyclo = cyclophosphamide, Doxo = doxorubicin, VCR = vincristine,
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The radiation dose delivered was according to the quality of
surgery and the histological response to chemotherapy. No radia-
tion was delivered after complete resection of a tumour containing
less than 5% of residual cells. In patients with an unresected or
incompletely resected primary, 45 Gy were delivered to the entire
tumour-bearing bone sparing one epiphyseal centre where
possible. Boosts of 10–15 Gy leading to a total dose of 55 to 60 Gy
were added to the bony tumour volume and the residual mass
whenever possible with a 2 cm safety margin. For the other
patients who had undergone complete resection but had more than
5% viable tumour cells in the specimen, the location of the tumour
and the percentage of residual tumour cells were taken into
account when deciding upon the radiation dose which was usually
40 Gy. 
Maintenance chemotherapy was identical for all patients, what-
ever the response to induction chemotherapy. It was started after
surgery, along with radiation therapy and consisted of weekly
vincristine, 1.5 mg/m2 (maximum 2 mg) for 11 weeks and dactin-
omycin combined with vincristine, 1.5 mg/m2 (maximum 2 mg)
every 2 weeks up to six doses. Subsequent therapy included six
additional courses of sequential cyclophosphamide and doxoru-
bicin at 3-week intervals. The total duration of therapy was
approximately 10 months with cumulative doses of 385 mg/m2
and 10.5 g/m2 for doxorubicin and cyclophosphamide respec-
tively. 
Statistical analyses 
All eligible patients were included in the analysis, regardless of
their compliance to the protocol. Overall, disease-free survival,
local control and metastasis-free survival were calculated
from the initiation of induction chemotherapy and estimated by
the Kaplan-Meier method (Kaplan and Meier, 1958). Patients
who failed to achieve a disease-free status, were considered as
having progressive disease since the first day of therapy. All
patients were included in the DFS curves. The statistical signifi-
cance of prognostic variables was tested by the log-rank test (Peto
et al, 1977). Multivariate analysis was then performed with the
Cox proportional hazard model (BMDP program). The multi-
variate analysis models were determined by the likelihood ratio
test. 
RESULTS 
From January 1988 to December 1991, 141 patients were treated
in 29 institutions in France and Belgium. Eighty-three (59%)
patients were male and 58 (41%) were female. The median age
was 11.9 years (range; 2–35 years). Forty-three patients (30%)
were 15 years or more and 17 (12%) were 20 years or more. Eighty
primary tumours (57%) were located in the trunk, 26 (18%) in
proximal (humerus and femur) and the remaining 35 (25%) in
distal parts of the extremities. 
At diagnosis, the largest tumour dimension was 8 cm or more in
84 patients (60%). The tumour volume was less than 100 ml in 61
patients (43%), between 100 ml and 200 ml in 34 patients (24%)
and greater than 200 ml in 46 patients (33%). 
Table 1 details tumour characteristics according to age compar-
ing the older group (> 15 years) to the younger one. Surprisingly,
the median tumour volume was not smaller in the younger group
as compared to the older group (126 ml versus 75). There was no
correlation between the tumour site and age. 
Ninety-two patients had an ES and 49 had a PNET. There was
no difference between patients with ES or PNET in terms of
gender, age, tumour site and volume. 
Clinical response to initial chemotherapy 
At completion of initial chemotherapy, clinical response was
assessed by imaging in 101 patients. Of these patients, 87 (85%)
were considered to be good responders with a complete response
in 35 patients and a partial response in 52. Fourteen patients (14%)
were considered to be poor responders. There was no response in 8
children: disease progressed in 2 and an early recurrence occurred
in 6 patients after an initial regression. Response could not be eval-
uated in 36 patients: 29 had no measurable soft-tissue mass after
biopsy and 7 had undergone resection of the bone tumour at diag-
nosis. Four patients were not evaluated clinically before surgery. 
There was no correlation between clinical response to chemo-
therapy and the site of the primary (trunk and extremities) nor
between response and the size of the primary. 
Surgery 
One hundred and eight patients (77%) underwent surgical resec-
tion of the primary tumour, either at diagnosis (7 cases) or after
induction chemotherapy (101 cases). Only four patients underwent
amputation because of poor response to chemotherapy in two
cases and a very large tumour of the humerus and of the tibia
respectively in two. One hundred and four patients had conserva-
tive surgery: either bone resection alone (45 patients) or bone
resection and reconstruction (59 patients). 
There was no significant correlation between the volume of the
primary and the modality used for local therapy. The median
volume of the resected tumours was 118 ml (range 1 to 2310 ml)
versus 138 (range 3 to 1300 ml) for the unresected tumours.
Surgery was performed as often in patients aged 15 years or under
as in patients who were older than 15 years (Table 1) but was
performed more often for extremity tumours (88%) than for trunk
tumours (67% P = 0.03).
Histological response to induction chemotherapy was evaluated
in 90 of the 101 patients who underwent surgery after induction
chemotherapy. Sixty-one patients (68%) were good responders with
minimal residual disease (less than 5% of residual cells); 38 of these
patients had no identifiable tumour in the resected bone. Fourteen
patients (15%) had an intermediate response (5–30% of residual
Table 1 Tumour characteristics of the tumour and local therapy according
to age 
< 15 years n = 98 ≥ 15 years n = 43
Volume of the primary 
median 126 ml 92 ml NS* 
range 2–2312 ml 4–1300 
Site of the tumour 
Trunk primary 52% 67% NS** 
Limb primary 48% 32%
Pelvic primary (19%) (26%) NS** 
Local therapy 
surgical resection ± RT 77% 74% NS** 
radiation therapy 60% 70%
*: t-test; ** chi square test. cells) and 15 patients (17%) were poor responders, with 30% or
more residual cells. Response to chemotherapy was not evaluated in
11 patients because the local pathologist lacked the expertise. The
characteristics of these last tumours were not different from their
evaluated counterparts in terms of site, size and outcome. 
Radiation therapy 
The median dose of radiation therapy delivered to patients who
did not undergo surgery (30 patients) was 60 Gy and ranged from
40 Gy (delivered to vertebral tumours) to 65 Gy. 
Among the 104 patients who underwent conservative surgery,
52 did not receive additional radiation therapy, 22 received 35 to
40 Gy after complete resection of their primary and 27 received
the classic high dose for positive or doubtful microscopic margins
in 14, an intermediate response to chemotherapy in 3 and because
the physician chose to do so in 10. Two patients developed metas-
tasis and two had both local and distant progression before the
beginning of radiation therapy. 
Overall treatment outcome 
The median follow-up of the 85 survivors was 8.5 years, (range
3.5–11 years) with follow-up exceeding 7 years in 75% of these
patients. 
Eight patients progressed under initial chemotherapy and
either did not achieve control of their primary with induction
chemotherapy or developed metastases very soon after radical
surgery. Fifty-five patients relapsed after initial tumour control.
Seventy-eight (55%) maintained a disease-free status. 
The site(s) of the first relapse was local (n = 18), both local and
distant (n= 8), or distant alone (n= 29). Among these metastases, 21
occurred in lungs, 10 in bones, 1 in bone and bone marrow, 4 in
lungs and bones and 1 in lungs, bones and bone marrow. Relapses
occurred at times ranging from 2 months to 102 months from the
diagnosis (mean, 27 months). Forty-three (78%) of the relapses
occurred within 3 years from the diagnosis. However, 4 were obser-
ved beyond 5 years (at 69, 73, 96 and 102 months from diagnosis). 
The projected overall survival (OS) at 5 years was 66% (se 4)
and disease-free survival (DFS) was 58% (se 4) (Figure 2).
Prognostic factors 
Table 2 lists disease-free survival rates according to the parameters
investigated for their prognostic significance for DFS. No correla-
tion was observed between these variables and the prognosis
(disease-free and overall survival) in terms of gender or age at
diagnosis. Figure 3 shows the 5-year DFS of patients younger than
15 years compared to that of older patients. The results would be
similar in terms of overall survival or if the cut-off age was 20 years. 
DFS did not vary significantly according to the site of the
primary tumour. Patients with distal extremity disease fared best
with 5-year DFS attaining 65% but this rate was not significantly
Prognostic factors in Ewing’s tumour 1649
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Table 2 Five year disease-free survival by prognostic variables, univariate analysis 
Variables No. Failure 5-year DFS (%) Standard error P
Gender 
male 83 38 56 5 NS (0.7) 
female 58 25 60 6
Age 
< 15 years 98 41 60 5 NS (0.5) 
≥ 15 years 43 22 53 7
< 20 years 125 56 57 4 NS (0.7) 
≥ 20 years 16 7 62 12
Site 
extremity 61 24 64 5 NS (0.3) 
trunk 80 39 54 4
distal extremity 35 12 65 8 NS (0.4) 
proximal extremity 26 12 58 10
trunk 80 39 54 5.5
non-pelvic 111 49 58 5 NS (0.6) 
pelvic 30 14 57 10
Histo 
ES1 92 43 55 5 NS (0.6) 
PNET2 49 20 63 7
LDH 
< 500 U/L 73 29 63 5.5 NS (0.07) 
> 500 U/L 23 13 43 10
ESR 
< 30 61 23 67 6 P = 0.04 
> 30 36 20 44 7
Size 
< 8 cm 57 17 72 6 P = 0.002 
≥ 8c m 8 4 4 6 4 9 5
< 100 ml 61 19 69 4 P = 0.006 
100–200 ml 34 17 55 8
≥ 100 ml 46 27 45 7
1: TES: Typical Ewing’s sarcoma; 2: PNET peripheral neuroectodermal tumour. 1650 O Oberlin et al 
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better than that of patients with proximal or axial tumours. DFS
was also similar for patients with pelvic disease as compared to
patients with non pelvic primary. There was no difference in
outcome between patients with tumours classified as ES or PNET. 
Initial pretreatment serum LDH value had no significant impact
on DFS (P = 0.07), whatever the chosen cut-off point, either 460
UI/L or 500 U/L. Erythrocyte sedimentation rate (ESR) at diag-
nosis was predictive of outcome. The probability of DFS was 63%
for patients with a normal ESR and only 43% for patients with
elevated ESR (P = 0.04).
The relationship between the size of the primary and outcome
was investigated taking into account the largest tumour dimension
as well as the volume. Figure 4 shows that DFS decreased
according to the size of the primary at diagnosis. DFS at 5 years
was 69% for patients whose primary was < 100 ml, 55% for
patients with a primary larger than 100 ml but smaller than 200 ml
and only 45% for patients whose primary was ≥ 200 ml (P =
0.006). Similar figures were obtained when the largest dimension
was taken into account (Table 2). Analysis of the pattern of failures
according to the size of the primary showed that the actuarial risk
of local failure was significantly higher for large tumours (> 100
ml) than for the small tumours (< 100 ml) (30% versus 12%
respectively), with the risk of metastases being similar for both
groups (22% versus 25% respectively). 
Volume of the tumour and ESR were strongly correlated and
ESR had no more impact on survival after adjustment on tumour
volume whereas tumour volume retains its prognostic value after
adjustment on ESR. 
DFS was correlated with clinical response to chemotherapy.
None of the patients who had a clinical poor response to
chemotherapy are disease-free survivors, whereas the DFS was
60% for patients who had good response. The DFS of the 36
patients who could not be evaluated because of an initial surgery or
the absence of measurable soft tissue was 76%, not significantly
different from the DFS of the good clinical responders (P = 0.08).
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Figure 2 Overall and disease-free survival rates (n = 141) 
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Figure 3 Disease-free survival rates for patients younger than 15 years 
(n = 98) and older than 15 years (n = 43) 
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Figure 4 Disease-free survival rates for patients with a primary tumour 
< 100 ml (n = 61), between 100 ml and 200 ml (n = 34) and ≥ 200 ml (n = 46) 
Table 3 Five-year disease-free survival by prognostic variables in patients treated by surgery ± radiation
therapy, univariate analysis 
Variables No. Failure 5-year DFS (%) Standard Error P
All patients 108 44 63 5
Site 
extremity 54 20 66 6
trunk 54 24 59 7 NS (0.53) 
Volume 
< 100 ml 47 16 66 7
100–200 ml 27 12 63 9
> 200 ml 34 16 58 8 NS (0.43) 
Radiological response 
Good response 69 25 65 8
Poor response 7 7 0 < 10–6
Histological response 
Good 61 16 75 5.5 
Intermediate 14 8 40 13
Poor 15 13 20 10 < 10–6Prognostic factors in Ewing’s tumour 1651
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The modality used for local therapy had a significant impact on
the prognosis. The 108 patients who underwent surgery fared
significantly better than the 33 patients who did not. DFS at 5
years was 63% (se 5) for the former compared to only 42% (se 8)
(P = 0.04) for the latter. 
In the sub-group of 108 patients who underwent surgery
(Table 3), the size of the tumour had no impact on DFS. Among
this sub-group, the DFS of the 47 patients with a small primary
(< 100 ml) was 66% (se 7) versus 60% (se 6) for the 61 patients
with a larger tumour (≥ 100 ml). In contrast, there was a signifi-
cant difference in DFS according to the size of the primary in the
sub-group of 33 patients treated with radiation therapy alone: 79%
(se 10) for small tumours versus only 13% (se 13) for large
tumours (P = 0.001). 
Figure 5 displays DFS curves according to the histological
response to chemotherapy. At 5 years, the DFS was 75% (se 5) for
the 61 patients with a good response to chemotherapy (less than
5% of residual cells), 48% (se 13) for the 14 patients with an inter-
mediate response (more than 5% and less than 30% residual cells)
and only 20% (se 10) for the 15 poor responders (≥ 30 residual
cells). This difference was highly significant P < 0.0001. 
Figure 6 shows the DFS curves for patients according to the
histological response to chemotherapy and the volume of the
primary. Patients with a good response to chemotherapy have a
62% DFS whatever the volume of the primary contrasting with the
low DFS of patients with a poor response, in whom there was no
impact of the primary tumour volume (P < 0.0001). 
A multivariate analysis was performed for the 90 patents for
whom the histological response to chemotherapy had been evalu-
ated. As shown in Table 4, only the histological response was
statistically related to disease-free survival. We did not test the
impact of clinical response on DFS since it was closely related
with the histological response: all the clinically poor responders
were also histological poor responders. 
Prognostic groups 
As the size of the primary was only predictive of outcome in
patients who did not undergo surgery and the histological response
to chemotherapy was the only prognostic factor in patients who
had surgery, these two criteria could be used to define two risk
groups with a totally different outcome, as shown in Figure 7. The
standard-risk group consists of 82 patients who either demon-
strated a good response to chemotherapy – less than 5% of residual
cells – (n = 61) or did not undergo surgery and had a small tumour
at diagnosis – < 200 ml – (n = 21) with a DFS of 72% at 5 years 
(se 5). The high-risk group consists of 48 patients who either
demonstrated a poor histological response – 5% of residual cells or
more – (n = 29) or did not undergo surgery but had a large tumour
at diagnosis – 200 ml or more – (n = 12). At 5 years, DFS was 26%
for these patients (se 7). 
Toxicity 
The protocol was fairly well tolerated. Chemotherapy courses did
not require hospitalization. There were no therapy-related deaths.
During the actinomycin + vincristine phase of chemotherapy, two
patients developed veno-occlusive disease which was life-threat-
ening in one case but the girl recovered without sequelae. During the
same phase, nine patients experienced severe weight loss due to
significant anorexia. The weekly vincristine (up to 11 weeks) led to
neuropathy in nine patients with abdominal pain in four and limb-
muscle pain in five. Seven patients developed haematuria. Two
episodes occurred during induction chemotherapy and resolved
with increased hydration; three occurred during maintenance
cyclophophamide chemotherapy with courses one, four and six; two
occurred after the end of treatment in patients who had received irra-
diation to the pelvis. Only one of these episodes led to the discontin-
uation of cyclophosphamide. Six patients had asymptomatic
echocardiography abnormalities that were mild and transient. 
The tolerance of radiation therapy in combination with actino-
mycin induced acute radiation reactions including six cases of
mucositis or diarrhea and nine cases of skin reactions. 
Thus far, four patients have developed a second primary. One girl
who was HIV-positive developed acute lymphoblastic leukaemia 18
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Figure 5 Disease-free survival according to histological response to
chemotherapy: Good response (< 5% cells; n = 61), intermediate response
(5–30% cells, n = 14), poor response (≥ 30% cells, n = 15) 
Figure 6 Disease-free survival rates according to histological response to
chemotherapy primary (good response : < 5% cells, poor response: ≥ 5%
cells) and tumour volume (small tumours: < 200 ml, large tumours: ≥ 200 ml) 
Table 4 Cox’s regression model for patients who had histological grading of
the resected tumour after initial chemotherapy (disease-free survival) 
Relative risk Confidence interval 95% P
Site 
extremity 1
trunk 1.1 0.6–2.2 NS (0.78)
Volume 
< 100 ml 1
100–200 ml 0.95 0.4–2.2
> 200 ml 0.93 0.4–2.2 NS (0.99) 
Histological response 
< 5% cells 1
> 5% cells 5 2.5–10 < 10–51652 O Oberlin et al 
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months after the end of treatment and died. One boy developed
hemispheric glioblastoma 3 years after treatment of a rib primary
and was alive without disease 4 years later. A 30-year-old woman
developed an ovarian carcinoma 5 years after the diagnosis of
Ewing’s sarcoma of the fibula. An 11-year-old girl with a Ewing’s
tumour of the ileum developed an osteosarcoma 8 years later within
the radiation field that had received a dose of 60 Gy. The cumulative
incidence of second cancers is 3% (se 1.5) and 5% (se 2.5) at 5 and
7 years after diagnosis. 
DISCUSSION 
When we planned the EW88 study, we were aware of the prelimi-
nary results of the protocol used by Hayes and colleagues in
Memphis to treat localized Ewing’s sarcoma. They had demon-
strated efficient prevention of metastases in their series; only 3 of
50 patients had developed isolated metastatic relapses (Hayes et al,
1989). 
The aims of the EW88 study was to achieve a better overall
outcome by improving local control using a more surgery-oriented
approach than that used in the Memphis study. 
The overall disease-free survival of 58% at 5 years observed in
the present study was similar to that observed in the above-
mentioned study. Arai updated the results of that study and
reported a 5-year relapse-free survival rate of 59% (Arai et al,
1991). These results also closely parallel the DFS reported by the
German Co-operative Ewing’s Sarcoma Study group (Hense et al,
1999) and compare favourably with the Paediatric Oncology
Group’s study which reported an EFS of 51% (Donaldson et al,
1998). As compared to the therapy used by the German group
(Hense et al, 1999), the chemotherapy was rather mild but tightly
scheduled focusing more on dose escalation in individual courses. 
There have been conflicting results in the literature concerning
the impact of neural differentiation on the prognosis. The results of
our study do not demonstrate a relationship between histological
features and the prognosis and do not support the concept that
tumours with more extensive neural differentiation may carry a
poorer prognosis. Bacci et al. recently found that EFS and OS rates
were significantly lower in patients with PNET than that observed
in patients with undifferentiated tumours (Bacci et al, 2000).
Results previously reported by Terrier et al, Jurgens et al, and
Parham et al, showed no differences in outcome according to
neurodifferentiation (Jurgens et al, 1993; Parham et al, 1999;
Terrier et al, 1995). 
The tumour size appears to be a significant factor both for local
tumour control and survival. This was first identified by
Mendenhall et al who reported a DFS of 87% in patients whose
primary lesions were grossly confined to bone compared to 20%
for those with extraosseous extension. The decrease in survival
related to soft tissue extension was due to an increase in distant
metastasis as well as local failure, and was independent of the site
of the primary (Mendenhall et al, 1983). The Memphis study
confirmed a significant correlation between the size of the primary
tumour and event-free survival (81% vs 49% for tumours < 8 cm
vs ≥ 8 cm) (Arai et al, 1991). 
The CESS81 study investigated the tumour volume and
confirmed that this parameter correlates strongly with 3-year DFS
(65% vs 32% for tumours < 100 ml vs ≥ 100 ml) (Sauer et al,
1987). In the CESS86 study, the treatment intensity was adapted to
the tumour volume and the results suggested a shift toward a
greater volume of 200 ml and above (Hense et al, 1999). 
The fact that there was no correlation between tumour volume
and the modality of local therapy is to be underlined and suggests
the advantage of the use of surgery compared to radiotherapy in
large tumours. 
Patients with pelvic primary had a 55% DFS and there was no
significant difference in outcome by tumour site whether lesions
were subdivided into two sites (pelvic and non-pelvic sites) or
three sites (central, proximal extremity, distal extremity). This is at
variance with the IESS-1 experience where patients with pelvic
disease had a worse survival than those with involvement of non-
pelvic sites (Nesbit et al, 1990), and with the POG study which
observed only a 24% EFS for patients with pelvic primary as
compared to 65% for patients with distal extremity and central
disease (Donaldson et al, 1998). 
The impact of age at onset of disease has been debated. Several
studies report a more favourable prognosis for younger patients
(Bacci et al, 2000; Craft et al, 1997; Kinsella et al, 1991). In our
study, tumour characteristics (site and volume), the modality used
for local therapy and outcome were similar in younger and older
patients. This corroborates the experience of the CESS 86 study
(Hense et al, 1999). 
The correlation between histologically-proven tumour necrosis
after preoperative chemotherapy and clinical outcome is well-
established in patients with osteosarcoma (Glasser et al, 1992).
There were doubts as to whether the same grading system would
be appropriate for Ewing’s sarcoma as this tumour shrinks with
preoperative chemotherapy and does not produce a similar osseous
and cartilaginous framework facilitating the estimation of tumour
necrosis based on the number of viable cells per unit area.
However in Ewing’s tumours, even after substantial shrinkage of
the soft-tissue tumour with preoperative chemotherapy, the delin-
eation of the initial tumour in the bone and the residual soft-tissue
are identifiable. Thus the value of extrapolation of the osteosar-
coma grading system was relevant. In the previous French cooper-
ative study EW84, this grading system was used in 31 patients who
underwent surgery after induction chemotherapy. All the 9 patients
who had more than 50% of residual cells relapsed as compared
with only 4 of the 22 patients who had less than 50% of residual
cells (P < 0.001) (Oberlin et al, 1992). Owing to considerable
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Figure 7 Disease-free survival rates according to risk groups. 
(1) Standard-risk group: tumours treated by surgery after initial
chemotherapy, with less than 5% of residual cells and small tumours (< 200
ml) treated by radiation therapy alone. (2) High-risk group: tumours treated
by surgery with ≥ 5% of residual cells and large tumors (> 200 ml) treated by
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changes in the chemotherapy regimens used in the EW84 study
and in the EW88 study we had to confirm that the histological
response remained prognostic. Furthermore, in the EW88 study, as
postoperative chemotherapy was modified compared to that
administered in the induction regimen by the introduction of
dactinomycin and vincristine, the value of the histological
response to cyclophosphamide and doxorubicin also warranted
documentation. We confirmed in 90 patients that this response was
strongly correlated with outcome and was independent of the size
of the primary at the time of the diagnosis. 
The histological response of the primary was first analysed in the
CESS81 study where the Salzer-Kuntschick’s grading system was
applied using a 10% cut-off. A large difference was found between
good responders (patients exhibiting less than 10% of viable
tumour) and poor responders. Of 38 good responders only 8
relapsed, whereas 11 of 16 poor responders did (P < 0.001). The
DFS at 3 years was 79% for good responders and 31% for poor
responders (P < 0.001). In that study, the multivariate analysis
showed that the influence of the histological response appeared to
have an edge over that of the tumour volume (Jurgens et al, 1988b). 
The Bologna team investigated a three-grade system based on
the absence of identifiable cells, the presence of microscopic or of
macroscopic nodules. The 5-year DFS estimates were, respec-
tively, 95%, 68%, and 34% (Picci et al, 1993). The same team
confirmed the absence of a correlation between the tumour volume
at diagnosis and chemotherapy-induced necrosis and that when the
histological response to chemotherapy was taken into account, the
tumour size was no longer statistically correlated with DFS as in
our present experience (Bacci et al, 2000). 
The prognostic factors found in this study (the histological
response to chemotherapy in patients who underwent surgery and
the size of the tumour in patients who did not) were the bases of
the following French EW93 study which was carried out from
1993 to 1999. In that study, chemotherapy was intensified in the
high-risk group. The randomized EuroEwing99 study which
started a few months ago compares the role of high-dose
chemotherapy with peripheral blood stem cell support to conven-
tional chemotherapy in this high-risk group of patients. This study
will also evaluate the value of an intensive up-front chemotherapy
based on ifosfamide, etoposide, vincristine and doxorubicin. 
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